Effect of montelukast on clinical score and cytokine levels of @entity1 for clinically diagnosed acute XXXX .

@entity1 @entity5924 @entity1800 @entity379 @entity3646 @entity687
BACKGROUND: Acute @entity5924 comprises a major cause for morbidity in @entity1 with @entity1800 which induces an immune inflammatory response that may produce long lasting harmful effects. Currently, there is no effective therapy for @entity5924 . OBJECTIVE: Our aim was to investigate the efficacy of five-day montelukast therapy in acute @entity5924 management. METHODS: The study included 50 @entity1 with acute @entity5924 . The @entity1 with first episode of acute @entity5924 were randomly assigned to receive daily montelukast dose of 4mg over five days after admission or no treatment. Plasma eotaxin, @entity3646 , @entity687 and @entity379 levels were evaluated before and after treatment by ELISA method. In the present study, the primary outcome measure was change in clinical severity score, whilst secondary outcome measures were changes in plasma eotaxin, @entity3646 , @entity687 , @entity379 levels. RESULTS: No significant differences was found in clinical severity score with five-day montelukast treatment (p>0.05, Mann-Whitney U test). There were no significant differences in plasma eotaxin, @entity3646 , @entity687 , @entity379 levels between the groups (p>0.05 Mann-Whitney U test). There was significant decrease in plasma @entity379 levels following five-day montelukast treatment (p=0.027, Wilcoxon). There were no significant differences in plasma @entity3646 , @entity687 , @entity379 levels between the groups after five-day montelukast treatment (p>0.05, Wilcoxon). There was significant increase in eotaxin levels after five-day montelukast treatment (p=0.009, Wilcoxon). CONCLUSION: Our study showed that montelukast affected plasma @entity379 and eotaxin levels after five days of treatment. Further studies are needed to demonstrate effects of montelukast on chemokine levels in @entity5924 .
